The Biomere team has validated several ocular disease models using state-of-the-art techniques including in-life imaging and terminal imaging and tissue collections. The team focuses on evaluating PK/PD characteristics and early safety profiles of novel therapies to treat ocular diseases. The Biomere site in the US has a variety of ocular models under development and has interest in collaborative model development on new and unique ocular models. Our combined preclinical and clinical research experience distinctively positions us to support our clients’ preclinical ophthalmic needs.
Dosing Techniques:
Currently, we have expertise in a range of dosing techniques in mouse, rat, rabbit and primate models. Most of the dosing methods are applicable to large and small animal species:
Suprachoroidal dosing is limited to rabbit and primate models.
Currently, Biomere has validated the following ocular disease models:
Check out our subretinal injection tutorials on the Concourse.
